<DOC>
	<DOCNO>NCT01082198</DOCNO>
	<brief_summary>RATIONALE : Vaccines make dendritic cell tumor antigen peptides person 's tumor cell may help body build effective immune response kill tumor cell . PURPOSE : This phase I/II trial study side effect best way give melanoma vaccine treat patient stage III melanoma surgery remove lymph node .</brief_summary>
	<brief_title>Melanoma Vaccine Treating Patients With Stage III Melanoma After Surgery Remove Lymph Nodes</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility adjuvant melanoma vaccine comprise autologous dendritic cell pulse tumor antigen peptides patient stage III melanoma follow lymphadenectomy . - Determine immune response ( skin test delayed-type hypersensitivity flow cytometric enumeration peripheral blood CD8+ lymphocytes produce IFN-Î³ ) regimen patient . - Determine clinical outcome ( disease-free survival , overall survival , adverse event ) patient treat regimen . OUTLINE : Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PBMCs ) bone marrow mononuclear cell . Autologous dendritic cell ( DCs ) prepare PBMCs bone marrow mononuclear cell expose various antigen peptide , autologous tumor cell lysate , available . Patients receive autologous DCs pulse melanoma-associated antigen peptide , autologous DCs pulse tumor lysates ( available ) , subcutaneously week 0 , 2 , 5 , 8 , 12 , 16 , 20 , 26 , 31 , 50 , 102 . Patients evidence disease may receive another booster injection 5 year start vaccination . Blood sample examine via flow cytometry skin test perform evaluate immune response .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage III melanoma Has undergone therapeutic lymphadenectomy More 1 lymph node involvement extracapsular extension metastatic melanoma cell ( stage N1bN3 disease accord AJCC 2002 ) HLA type A1 and/or A2 A3 ( autologous tumor lysate available ) No presence distant metastases PATIENT CHARACTERISTICS : No malignancy No evidence lung , heart , liver , renal failure severe neurologic disorder No autoimmune disease atopic allergy No HIV infection presence antiHIV antibodies No presence hepatitis B surface antigen antibody hepatitis C virus PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage III melanoma</keyword>
</DOC>